195 related articles for article (PubMed ID: 25618774)
21. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
22. [BRAF mutation testing for the choice of melanoma treatment].
Imianitov EN
Arkh Patol; 2012; 74(5):65-71. PubMed ID: 23342664
[TBL] [Abstract][Full Text] [Related]
23. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics.
Smalley KS; Herlyn M
Ann N Y Acad Sci; 2005 Nov; 1059():16-25. PubMed ID: 16382039
[TBL] [Abstract][Full Text] [Related]
24. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
Wellbrock C; Marais R
J Cell Biol; 2005 Aug; 170(5):703-8. PubMed ID: 16129781
[TBL] [Abstract][Full Text] [Related]
25. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA
Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma.
McKee CS; Hill DS; Redfern CP; Armstrong JL; Lovat PE
Exp Dermatol; 2013 Nov; 22(11):767-9. PubMed ID: 24118207
[TBL] [Abstract][Full Text] [Related]
27. Cancer research. Melanoma drug vindicates targeted approach.
Garber K
Science; 2009 Dec; 326(5960):1619. PubMed ID: 20019269
[No Abstract] [Full Text] [Related]
28. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
29. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
[TBL] [Abstract][Full Text] [Related]
30. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
31. Targeted therapy resistance mechanisms and therapeutic implications in melanoma.
Chen G; Davies MA
Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945
[TBL] [Abstract][Full Text] [Related]
32. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
Parakh S; Murphy C; Lau D; Cebon JS; Andrews MC
J Clin Pharm Ther; 2015 Feb; 40(1):121-3. PubMed ID: 25382067
[TBL] [Abstract][Full Text] [Related]
33. Transdifferentiation of Melanoma Cells by the Reprogramming Factors Attenuates Malignant Nature In Vitro and In Vivo.
Takaishi M; Sano S
J Invest Dermatol; 2019 Jan; 139(1):254-257. PubMed ID: 29990471
[No Abstract] [Full Text] [Related]
34. Mitochondrial metabolic reprograming via BRAF inhibition ameliorates senescence.
Kim JW; Kuk MU; Choy HE; Park SC; Park JT
Exp Gerontol; 2019 Oct; 126():110691. PubMed ID: 31421186
[TBL] [Abstract][Full Text] [Related]
35. Mitochondrial Metabolism in Melanoma.
Huang C; Radi RH; Arbiser JL
Cells; 2021 Nov; 10(11):. PubMed ID: 34831420
[TBL] [Abstract][Full Text] [Related]
36. Screening of metabolic modulators identifies new strategies to target metabolic reprogramming in melanoma.
Abildgaard C; Rizza S; Christiansen H; Schmidt S; Dahl C; Abdul-Al A; Christensen A; Filomeni G; Guldberg P
Sci Rep; 2021 Feb; 11(1):4390. PubMed ID: 33623106
[TBL] [Abstract][Full Text] [Related]
37. Emerging targets for combination therapy in melanomas.
Saito Rde F; Tortelli TC; Jacomassi MD; Otake AH; Chammas R
FEBS Lett; 2015 Nov; 589(22):3438-48. PubMed ID: 26450371
[TBL] [Abstract][Full Text] [Related]
38. Changes in the Turnover of the Cellular Proteome during Metabolic Reprogramming: A Role for mtROS in Proteostasis.
García-Aguilar A; Martínez-Reyes I; Cuezva JM
J Proteome Res; 2019 Aug; 18(8):3142-3155. PubMed ID: 31293153
[TBL] [Abstract][Full Text] [Related]
39. Exploring metabolic reprogramming in melanoma via acquired resistance to the oxidative phosphorylation inhibitor phenformin.
Pistoni M; Tondelli G; Gallo C; Torricelli F; Maresca A; Carelli V; Ciarrocchi A; Dallaglio K
Melanoma Res; 2020 Feb; 30(1):1-13. PubMed ID: 31116160
[TBL] [Abstract][Full Text] [Related]
40. Mitochondrial Mechanisms of Metabolic Reprogramming in Proliferating Cells.
Sousa MI; Rodrigues AS; Pereira S; Perestrelo T; Correia M; Ramalho-Santos J
Curr Med Chem; 2015; 22(20):2493-504. PubMed ID: 25973982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
